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a b s t r a c t
Rabbit antithymocyte globulin (Thymoglobulins) is commonly used as graft-versus-host disease (GvHD)
prophylaxis. Since we found similar total CD8 T cell numbers in patients with and without Thymoglo-
bulins therapy within the ﬁrst six months after allogeneic hematopoietic stem cell transplantation, we
have analyzed the reconstitution of the CD8 T cell compartment in detail. After T cell-depletion, higher
and more sustained proliferative capacity of memory CD8 T cells resulted in their rapid expansion,
whereas the fraction of naive CD8 T cells decreased. Importantly, this shift towards effector memory CD8
T cells did not accelerate the incidence of GvHD.
& 2013 The Authors. Published by Elsevier Ltd.
1. Introduction
One of the major complications associated with allogeneic
hematopoietic stem cell transplantation (alloHSCT) is the high
incidence of acute graft-versus-host disease (GvHD) caused by
donor T-lymphocytes. Depletion of donor T-lymphocytes is a well-
established therapeutic option for GvHD-prophylaxis. Recently, we
showed a sustained depletion of conventional and regulatory CD4
T cells in patients treated with ATG-Genzyme™ (Thymoglobulins,
ATG-G) [1], a polyclonal antibody preparation containing a broad
spectrum of antibodies directed against T cells [2] and potentially
thymic stromal cells. Interestingly, total CD8 T cell counts were
similar in ATG-G treated and untreated patients[1]. In principle,
T cell recovery after transplantation can take place through thymus
dependent regeneration as well as by proliferation of existing
T cells [3].
Here, we addressed whether the rapid CD8 T cell recovery after
ATG-G depletion resulted from accelerated CD8 T cell regeneration
or increased peripheral CD8 T cell proliferation and in how far this
inﬂuenced GvHD incidence. Therefore, we studied the distribution
of different CD8 T cell subsets and their proliferative capacity in
ATG-G treated patients of the same patient cohort.
2. Material and methods
A detailed description of methods and patient cohorts can be
found in Na et al. [1] (approval by the Charité – Berlin local ethics
committee no. EA4/128/09). Brieﬂy, we compared CD8 T cell
reconstitution in 12 alloHSCT patients receiving ATG-G according
to standard procedure protocols (ATG-G group, for dþ180: n¼11)
with 8 alloHSCT patients not receiving ATG-G (noATG-G group, for
dþ180: n¼3). Patient characteristics and clinical outcome are
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presented in Table 1. Indications for transplantation were hema-
tologic malignancies in all cases (AML n¼17, ALL n¼2, CLL n¼1).
Patients received ATG-G additionally to standard conditioning
regimens if transplanted with grafts from matched-unrelated
donors (MUD) as opposed to matched related donors (MRD) in
the noATG-G group. One patient receiving an MUD graft did not
receive ATG-G.
Multicolor ﬂow cytometry (Becton Dickinson LSRII supported
by FlowJo 9.3 software, TreeStar) was used to identify different
CD8 T cell subsets after standard staining procedures of peripheral
blood mononuclear cells (PBMC) from fresh heparinized blood
samples. The following antibodies were used to characterize the
CD8 T cell subsets: anti-CD3 APC/Cy7 (clone UCHT1; BioLegend),
anti-CD4 Alexa Fluor 700 (clone RPA-T4; BioLegend), anti-CD8
V500 (clone RPA-T8; BD Biosciences), anti-CD45RA PerCP/Cy5.5
(clone HI100; BioLegend), anti-CD45RO Paciﬁc Blue (clone UCHL1;
BioLegend), and anti-CD197 (CCR7) Alexa Fluor 488 (clone TG8/
CCR7; BioLegend). For evaluation of Ki67 expression stainings
were performed using anti-CD3 APC/Cy7 (clone UCHT1; Bio-
Legend), anti-CD4 Alexa Fluor 700 (clone RPA-T4; BioLegend),
anti-CD8 V500 (clone RPA-T8; BD Horizon), anti-CD45RA
eFlour605 (clone HI100; eBioscience) and anti-Ki67 FITC (clone
B56, BD Pharmingen). CD3 T cell counts were obtained by staining
whole blood samples with CD3-Cy5 (clone UCTH-1, DRFZ, Berlin)
and using BD TruCountTM controls (BD Biosciences). For group
comparisons the Mann-Whitney-U test was used (GraphPad Soft-
ware, La Jolla, CA).
3. Results
Analysis of the CD3 T cell compartment revealed comparable
cell counts in both groups except day 15 after transplantation with
signiﬁcantly lower absolute counts in the ATG-G group (Fig. 1A;
46.29 cells/μl711.61 (SEM) versus 365.1 cells/μl7102.8 (SEM),
po0.005). The share of CD8þ T cells was signiﬁcantly higher in
the ATG-G group at all time points post transplantation except
dþ180 (Fig. 1B). On day 15 we observed high rates of CD8 T cell
proliferation only in the ATG-G group, as shown by Ki67 staining
(Fig. 1C,D; 49.0%76.8% in ATG-G group versus 11.0%72.6% in
noATG-G group on dþ15, po0.01). We then compared prolifera-
tive activity of CD45RAþ and CD45RA CD8 T cells within the
ATG-G group. Proliferation rates of CD45RA CD8 T cell subsets
were higher at all time points after transplantation as compared to
CD45RAþ CD8 T cell subsets with signiﬁcant differences on days
60, 90 and 180 (Fig. 1E,F). At day 15 CD45RAþ CD8 T cells also
showed a strikingly high proportion of Ki67þ cells (35.1%77.7%).
However, at day 30 this share dropped (3.2%70.9%) and
remained low.
Next, we used a gating strategy originally suggested by Sallusto
et al. [4] to assess naive (CD45RAþCCR7þ), central memory (CM,
CD45RACCR7þ), effector memory (EM, CD45RACCR7) and
effector (CD45RAþCCR7) CD8 T cells (Fig. 2A). We observed
signiﬁcantly higher frequencies of EM CD8 T cells in the ATG-G
group at all time points except dþ180 (Fig. 2B). In contrast,
frequencies of naive CD8 T cells were signiﬁcantly lower in ATG-
G treated patients compared to patients without ATG-G treatment
at all time points post transplantation (Fig. 2C). The frequencies of
CM and effector CD8 T cells were comparable in both groups
(Fig. 2D, E).
4. Discussion
Investigating the impact of ATG-G as a T cell depleting strategy
[2], as expected we observed lower CD3 T cell counts in the ATG-G
group. Considering the half-life of ATG-G (clearance to sub-
therapeutic levels by a median of 1779 days [5]), unsurprisingly
there was only a signiﬁcant difference of CD3 T cell counts early
after alloHSCT. The observed persistent increase of CD8 T cell
frequencies is likely to be mainly due to decreased CD4 T cell
counts as previously described [1].
Table 1
Patient characteristics and clinical outcome.
Patient
no.






ATG-G group 1 50 AML MUD Cy/TBI dþ15 I
2 mg/kg/day on days 3,2,1 before
transplantation
2 27 AML MUD Cy/TBI dþ18 III
3 28 ALL MUD Cy/TBI dþ15 I
4 48 AML MUD Cy/TBI x dþ12 I
5 57 ALL MUD Cy/TBI dþ13 III
6 58 AML MUD Fludara/Treo dþ16 I
7 50 AML MUD Cy/TBI dþ14 None
8 69 AML MUD FLAMSA dþ13 II
9 60 AML MUD Fludara/Treo dþ16 I
10 47 AML MUD Cy/TBI dþ13 None
11 57 AML MUD Fludara/8 Gy TBI dþ17 None
12 48 AML MUD Cy/TBI dþ13 I
noATG-G group 13 58 AML MRD Fludara/Treo dþ15 II
14 41 AML MRD FLAMSA x dþ8 None
15 34 AML MRD Cy/TBI x dþ17 None
16 57 AML MRD Cy/TBI x dþ15 II
17 40 AML MUD Bu/Cy x dþ30 III
18 61 AML MRD MitoFLAG x dþ17 I
19 57 AML MRD Fludara/Treo dþ19 II
20 67 CLL MRD Fludara/2 Gy TBI dþ17 II
Abbreviations: AML, acute myeloid leukemia; ALL, acute lymphatic leukemia; Bu, busulfane; CLL, chronic lymphatic leukemia; Cy, cyclophosphamide; FLAMSA, Fludarabin,
Cytosin-Arabinosid and Amsacrin; Fludara, ﬂudarabine; aGvHD, acute graft-versus-host disease; Gy, Gray; MitoFLAG, Mitoxantrone, Fludarabine, Cytosin-Arabinosid and
granulocyte-colony stimulating factor; MMF, mycophenolate mofetil; MTX, methotrexate; TBI, total body irradiation; Treo, treosulfane.
a Age at transplantation.
b Deceased between days þ90 and þ180 after transplantation.
c Time to leukocyte engraftment in days after transplantation.
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Analysis of the CD8 T cell compartment in detail revealed a shift
towards high EM and low naive CD8 T cell frequencies in the
ATG-G group. This shift was observed up to dþ180 after alloHSCT,
suggesting indirect long-term effects resulting from ATG-G treat-
ment. Low shares of naive CD8 T cells could be the consequence of
a rapid transition into the memory pool or thymic impairment due
to ATG-G as previously suggested for CD4 T cell regeneration [1].
The rapid increase of EM CD8 T cells appears to be driven mainly
by homeostatic mechanisms in the ATG-G depleted host, since
concomitant high rates of CD8 T cell proliferation were found
around day 15 in the ATG-G group only. This hypothesis is
supported by consistently higher proliferation rates of CD45RA
CD8 T cells as compared to CD45RAþ CD8 T cells within the ATG-G
group. However, it has previously been shown that changes
towards an EM phenotype from other subsets such as naive CD8
T cells are also induced by T cell receptor stimulation and that CM
CD8 T cells undergo various phenotypic changes upon cytokine
stimulation, amongst others towards an EM phenotype [6]. It
cannot be excluded that both these mechanisms contribute to
the expansion of the EM CD8 T cell subset. Yet, the same reports
also support the notion that EM CD8 T cells are especially receptive
to cytokine stimulation [6] thus favoring the hypothesis of homeo-
static proliferation.
In line with larger clinical studies demonstrating ATG-G efﬁ-
cacy especially for prevention of severe acute GvHD (reviewed in
[7]), acute GvHD-rates in both patient groups in our study were
similar even though ATG-G treated patients were transplanted
with MUD grafts as opposed to MRD grafts in the noATG-G group
and thus were at higher risk of GvHD (acute GvHD ATG-G group
versus noATG-G group: Grade I and II 58% versus 63%, Grade III
and IV 17% versus 13%). Consequently, the initial T cell depletion by
ATG-G limited GvHD in MUD transplantations as intended. Yet,
this also suggests that the signiﬁcant expansion of EM CD8 T cells
in the ATG-G group is not driving GvHD. Results from mouse
studies equally suggest that memory CD8 T cells are less potent in
mediating acute GvHD than naive CD8 T cells [8]. EM CD8 T cells
appear to be favorable over CM CD8 T cells in this respect in mice
[9,10]. Likewise, in vitro studies with human material from healthy
Fig. 1. Proliferative capacity of CD8 T cells after alloHSCT. Mean values of (A) CD3 T cell counts (cells/μl7standard error of mean (SEM)) and (B) CD8 T cell frequencies
(%7SEM) are shown. Proliferation of total (C, D) and CD45RAþ and RA- (E, F; ATG-G group only) CD8 T cells was measured by Ki67 analysis. For statistical evaluation the
Mann Whitney U test was used. npo0.05; nnpo0.01; nnnpo0.005.
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donors indicate an increased alloreactivity of naive CD8 T cells as
compared to memory CD8 T cells under certain conditions [11].
In summary, our data suggest that rapid recovery of CD8 T cells
after ATG-G induced T cell depletion in alloHSCT patients is due to
peripheral homeostatic proliferation of EM CD8 T cells and not due
to accelerated regeneration of naive CD8 T cells. This leads to a
characteristic shift to EM CD8 T cells that is not associated with
higher rates of GvHD.
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